Wnt Signaling in Renal Cancer
The DOI matches its Crossref record.
Abstract
About one fourth of people diagnosed with kidney cancer in 2007, are expected to die of this disease within 5 years from the date of diagnosis. Recent years have produced novel drugs, some with FDA approval, and many in clinical trials, all showing very discrete results. Failure in finding effective treatments to improve survival with drugs mainly targeting VEGF and its downstream effectors, urges to shift the drug development targets to other unexploited pathways shown to be also involved in renal cancer. Several studies show alterations in the Wnt signaling pathway, many of which differ from those implicated in other human cancers. Unlike colorectal or hepatocellular carcinomas, where APC and axin mutations, respectively, are the main Wnt signaling deregulating event, renal carcinomas seem to be affected by other factors. Recent studies have presented VHL, a tumor suppressor gene strongly associated with renal cell carcinoma, as a beta-catenin target. This confirms that Wnt signaling is likely playing a central role during renal carcinoma development, which needs to be considered and addressed to treat this disease. This review outlines briefly the molecular biology of the most common renal cancers and the drug treatments currently used to treat the disease. The canonical Wnt pathway is reviewed more carefully adding specific features in a renal carcinoma context, which present potential targets for drug development and biomarker use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wnt Signaling in Renal Cell Carcinoma
Xu, Q., Krause, M., Samoylenko, A., & Vainio, S. (2016) · Cancers · doi:10.3390/cancers8060057 · Cited by 99
Stabilization of MCRS1 by BAP1 Prevents Chromosome Instability in Renal Cell Carcinoma
Peng, J., Ma, J., Li, W., Mo, R., Zhang, P., Gao, K., Jin, X., Xiao, J., Wang, C., & Fan, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.013 · Cited by 46
Kim, N. Y., Jung, Y. Y., Yang, M. H., Chinnathambi, A., Govindasamy, C., Narula, A. S., Namjoshi, O. A., Blough, B. E., & Ahn, K. S. (2022) · Biochimie · doi:10.1016/j.biochi.2022.05.018 · Cited by 24
Metadata
- Authors
- Guillen-Ahlers, H.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-07-01
- Volume
- 9
- Issue
- 7
- Pages
- 591-600
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W1984374221
- Cited by
- 43
- References
- 0
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wnt Signaling in Renal Cancer. https://app.cochat.ai/papers/10.2174/138945008784911813
- The paper
- Guillen-Ahlers, H. (2008). Wnt Signaling in Renal Cancer. Current Drug Targets. https://doi.org/10.2174/138945008784911813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.